1. Introduction {#sec1-cancers-11-01283}
===============

Intimal sarcomas (IS) are rare mesenchymal tumors that involve the innermost layer of large vessels, most commonly seen in pulmonary arteries \[[@B1-cancers-11-01283],[@B2-cancers-11-01283],[@B3-cancers-11-01283],[@B4-cancers-11-01283]\]. Diagnosing this sarcoma has proved challenging despite the criteria set by the World Health Organization (WHO), as it is largely undifferentiated and histologically variable even within the same host \[[@B1-cancers-11-01283],[@B2-cancers-11-01283],[@B5-cancers-11-01283],[@B6-cancers-11-01283],[@B7-cancers-11-01283]\]. This tumor has the ability to differentiate into other types of sarcomas such as leiomyosarcoma and angiosarcoma \[[@B1-cancers-11-01283],[@B3-cancers-11-01283],[@B5-cancers-11-01283]\]. Since intimal sarcomas are found post-operatively or at autopsy, the true incidence of this disease entity is unknown and likely underestimated \[[@B8-cancers-11-01283]\]. Clinical presentation can be non-specific and variable, but these tumors can mimic signs and symptoms of thromboembolism which delays diagnosis \[[@B3-cancers-11-01283],[@B5-cancers-11-01283],[@B9-cancers-11-01283]\]. The clinical course is often aggressive, with over 50% of patients having metastasis upon diagnosis \[[@B5-cancers-11-01283],[@B10-cancers-11-01283]\]. There are no standardized treatments or protocols for this type of cancer \[[@B11-cancers-11-01283]\]. Intimal sarcoma has been shown to be highly resistant to conventional chemotherapies such as anthracyclines, topoisomerase inhibitors, and alkylating agents \[[@B5-cancers-11-01283],[@B11-cancers-11-01283],[@B12-cancers-11-01283],[@B13-cancers-11-01283],[@B14-cancers-11-01283]\]. Prognosis is poor, with a median survival of 12--13 months with radical surgery aimed at complete resection \[[@B2-cancers-11-01283],[@B5-cancers-11-01283],[@B11-cancers-11-01283]\]. The challenging dynamic on a clinical and histologic level necessitates a comprehensive genetic approach to diagnose and develop targeted treatment plans. Unfortunately, limited data is available on the molecular characteristics of this tumor.

Attempts to elucidate the genomic profile of this rare tumor have been accomplished by only a few studies, but have emphasized the involvement of *PDGFRA*, a gene encoding tyrosine kinase receptors for platelet-derived growth factor. A case report on cardiac intimal sarcoma found copy gains in *PDGFRA*, *KIT*, *STAT6*, *GLI-1*, *CKD4*, *HMGA2*, and *MDM2* (a negative regulator of p53) using whole exome sequencing (WES) and array-comparative genomic hybridization (aCGH) \[[@B4-cancers-11-01283]\]. They also discovered concurrent *PDGFRα* amplification and *PDGFRβ* R709H mutation in intimal sarcoma \[[@B4-cancers-11-01283]\]. The largest study of cardiac sarcomas analyzed tissue samples from 100 cases, and found intimal sarcomas to be the most frequent subtype of cardiac sarcoma, with amplification of *MDM2* in all cases. They also identified copy gains of *CDK4*, *HMGA2*, *DDIT3*, and *GLI* coinciding with 12q12--15 region via immunohistochemical analysis and confirmed with fluorescence in situ hybridization (FISH), real-time polymerase chain reaction (RT PCR), and aCGH. Other findings included copy gains in 4q12 with *KIT* and *PDGFRA*, 7p12 with *EGFR*, and copy number loss of *CDKN2A* in 9p21 \[[@B1-cancers-11-01283]\]. Another study of IS, which was the first to propose *PDGFRA* as a molecular hallmark for intimal sarcomas, found copy number gains of *PDGFRA*, *EGFR*, and *MDM2* in 8 patients using FISH and aCGH with consistent activation of *PDGFR* and *EGFR* confirmed by western blotting \[[@B2-cancers-11-01283]\]. Interestingly, a case report of IS in the abdominal aorta found intratumoral heterogeneity of *PDGFRA* amplification \[[@B7-cancers-11-01283]\]. The tumor cells with the lowest degree of atypia, usually at the site of origin of the tumor, were not associated with overexpression of *PDGFRA*. Conversely, cells with the most atypia and aberrancy were found to have over-amplification of *PDGFRA*, suggesting *PDGFRA* is needed for tumorigenesis and the biopsy site is crucial for molecular studies \[[@B7-cancers-11-01283]\]. Overall, these studies found recurrent amplification of *PDGFRA*, *PDGFRB*, *CKD4*, and *MDM2*, implicating their involvement in the tumorigenesis process. No study has found somatic mutations leading to overexpression, or unique genetic fusions. Thus, the mechanism by which these genes are overexpressed is likely to be through gene amplification \[[@B1-cancers-11-01283],[@B2-cancers-11-01283],[@B12-cancers-11-01283],[@B15-cancers-11-01283]\].

Other malignancies with dysregulated *PDGFRA* signaling, such as gastrointestinal stromal tumors (GIST), have received treatment with tyrosine kinase inhibitors (TKI) \[[@B16-cancers-11-01283]\]. Ex vivo assays performed on tumor cell cultures exposed to a TKI for two hours from a single patient case with IS, demonstrated a dose-response in decreasing *PDGFRA* phosphorylation confirmed by western blotting \[[@B2-cancers-11-01283]\]. One case series had 4 of 13 patients with IS initiated on a TKI, but given the molecular complexity of the tumor, remission was not achieved \[[@B5-cancers-11-01283]\]. Unfortunately, as these tumors involve major vessels they are excluded from any potential early phase clinical trials.

2. Results {#sec2-cancers-11-01283}
==========

To identify common and unique genetic alterations in IS for targeted therapy, we queried data from the American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) genomic database and cataloged and assessed genomic alterations and their clinical utility. As shown in [Figure 1](#cancers-11-01283-f001){ref-type="fig"}, intimal sarcoma comprises only 0.6% of all sarcomas in this large database \[[@B17-cancers-11-01283]\]. Among the 13 patients analyzed with intimal sarcoma, the median age was 46 (range 18--76); eight were female (61%) (see [Table 1](#cancers-11-01283-t001){ref-type="table"}). Genomics were performed on tissue from the primary tumor in ten patients and metastatic site in three patients.

Copy number alterations were available for 12 patients (see [Figure 2](#cancers-11-01283-f002){ref-type="fig"}). We identified amplifications in *MDM2* (*n* = 9, 75%), *CDK4* (*n* = 6, 50%), *TERT* (*n* = 6, 50%), *KIT* (*n* = 4, 33%), *KDR* (*n* = 3, 25%), *PDGFRA* (*n* = 4, 33%), *NOTCH2* (*n* = 2, 17%), *ERBB3* (*n* = 3, 25%), and *GLI1* (*n* = 3, 25%). Copy number losses in *CDKN2A* and *CDKN2B* were observed in three tumors (25%).

Next-generation sequencing revealed 38 somatic nonsynonymous mutations (33 missense, four frame shift, one nonsense, and one splice region) in intimal sarcoma tumors from nine patients (see [Table 2](#cancers-11-01283-t002){ref-type="table"}). Among these mutations, M772V (c.2314A \> G) and D850V (c.2549A \> T) were found in *PDGFRB* from two different primary tumors. The primary tumor sample with the D850V mutation in *PDGFRB* had concurrent mutations in *PTCH1* (c.961C \> A), *ATR* (c.4704C \> G), and *CDKN1A* (c.419_420delGA). Potentially actionable genes are highlighted in green in [Table 2](#cancers-11-01283-t002){ref-type="table"}.

Genomic rearrangement events included only a *PDE4DIP-NOTCH2* and a *MRPS30-ARID2* fusion (see [Table 3](#cancers-11-01283-t003){ref-type="table"}). Interestingly, co-occurring alterations included a *NOTCH2* copy number gain in the *PDE4DIP-NOTCH2* fusion tumor and *PDGFRB* mutations in both fusion-positive cases.

We sought to analyze clinical trial results, but of the 406 sarcoma patients enrolled in clinical trials there were no patients with intimal sarcoma in a large Phase 1 clinic at the University of Texas MD Anderson Cancer Center. We hypothesize this was due to exclusion based on the location of their tumors.

3. Discussion {#sec3-cancers-11-01283}
=============

There is a large amount of heterogeneity in the presentation, histology, and genomic profile of intimal sarcomas \[[@B1-cancers-11-01283],[@B2-cancers-11-01283],[@B3-cancers-11-01283],[@B4-cancers-11-01283],[@B18-cancers-11-01283]\]. The molecular variability and aggressive nature of this cancer makes it a challenging entity to diagnose and treat. Case reports and series have shown conventional chemotherapy with limited success, and curative radical surgery prolonging survival to a little over a year \[[@B5-cancers-11-01283],[@B11-cancers-11-01283],[@B12-cancers-11-01283],[@B13-cancers-11-01283]\]. To our knowledge, there are no prospective clinical trials for patients with intimal sarcoma. These patients with intimal sarcoma will need to be included in clinical trials to determine which patients would benefit from genomically-matched therapies.

Our study confirmed the recurrence of copy number gains in *MDM2* and *CDK4* that coincide with the location 12q12--15, and *PDGFRA* in 4q12, as described in prior studies. The amplification of these genes strongly suggests that *PDGFR* and *MDM2* pathways are important for tumorigenesis in IS. MDM2 inhibitors under investigation have demonstrated responses in early phase clinical trials in MDM2 amplified soft tissue sarcomas (with or without CDK4 co-amplification) such as liposarcoma and synovial sarcoma \[[@B19-cancers-11-01283]\]. Our data support the use of NGS on intimal sarcomas to identify MDM2 amplification and consideration for such trials. Thirty-three percent were found to have *PDGFRA* amplification, but this can be explained by the choice of biopsy site due to intratumoral heterogeneity \[[@B7-cancers-11-01283]\]. New mutations in *PDGFRB* found in our study may have implications for tumorigenesis and therapeutic options as well.

We also found novel somatic mutations in another receptor kinase gene such as *ALK*, which is known to be mutated or amplified in various other cancers such as lymphomas and non-small cell lung cancers \[[@B20-cancers-11-01283]\]. However, the ALK E1460Q mutation is outside the tyrosine kinase domain and may not be relevant clinically. Other mutations identified include ATM/ATR, and *PTCH1*, a tumor suppressor that is part of the hedgehog signaling pathway involved in tumorigenesis \[[@B21-cancers-11-01283],[@B22-cancers-11-01283]\]. A cell checkpoint kinase mutation, which is upstream from p53 in the signaling pathway, was also seen. All of these genes could be potential targets for treatment.

Additional findings of interest include fusion proteins involving *NOTCH2-PDE4DIP* and *ARID2-MRPS30* and copy number gains in *NOTCH2*. Irregular NOTCH2 signaling has been associated with the initiation and progression of multiple cancers including liver, brain, and gastric cancers along with lymphomas \[[@B23-cancers-11-01283]\]. In addition to NOTCH2, mutations in *ARID2*, a possible tumor suppressor, are also found in hepatocellular carcinomas \[[@B24-cancers-11-01283]\]. The counterparts of these fusion proteins, such as MRPS30 and PDE4DIP, may also be associated with an increased risk for breast cancer and leptomeningeal disease progression, respectively \[[@B25-cancers-11-01283],[@B26-cancers-11-01283]\]. Interestingly, both fusion proteins were found in primary tumors, but their effect on the tumorigenesis of intimal sarcomas is unknown and will require further investigation.

Limitations of this study include the sample size, which given the rarity of disease and biopsy site is likely due to intratumoral heterogeneity. Intimal sarcoma patients are currently not enrolled in clinical trials due to the location of the tumors in major vasculature. Since we noted actionable alterations in MDM2, CDK4, PDGFRA, and NOTCH2, as well as copy number losses in CDKN2A and CDKN2B, our study has clinical implications. There are now three US FDA approved CDK4/6 inhibitors for breast cancer, Palbociclib (IBRANCE^®^, Pfizer Inc.), ribociclib (Kisqali^®^, Novartis Pharmaceuticals Corporation), and abemaciclib (VERZENIO^™^, Eli Lilly and Company). Given the multiple aberrations seen in the CDK pathway, CDK4/6 inhibitors may be an option in clinical trials or off-label based on molecular profiling data. In addition, some of these tumors may be responsive to drugs that are already approved for the treatment of sarcomas like Pazopanib (Votrient^®^), which is a multi-kinase VEGF based inhibitor that has activity against the PDGFR pathway as well. Other novel TKIs and MDM2 antagonists should be evaluated as treatments for advanced IS. In addition, the role of ATM/ATR, NOTCH2, and PTCH1 should be studied as potential therapeutic targets. Investigators should be encouraged to enroll these patients with specific molecular aberrations to basket trials.

4. Materials and Methods {#sec4-cancers-11-01283}
========================

We queried the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) database (version 5) \[[@B27-cancers-11-01283]\]. The GENIE registry derives existing CLIA-/ISO-certified genomic data \[[@B28-cancers-11-01283]\]. Published records in Pubmed/Medline were reviewed for genomic data from several different platforms. Retrospective records were abstracted to appraise the benefit of using a targeted therapy approach in a large Phase 1 clinic at the University of Texas MD Anderson Cancer Center.

Ethics Statement: All AACR GENIE project data has been de-identified using the HIPAA Safe Harbor Method. Analyses were retrospective and were performed in accordance with the AACR GENIE Human Subjects Protection and Privacy policy. Institutional Review Board (IRB) details are provided in the AACR GENIE Data Guide \[[@B28-cancers-11-01283]\].

5. Conclusions {#sec5-cancers-11-01283}
==============

Comprehensive genomic profiling may be considered for intimal sarcoma, both to confirm diagnosis and to explore treatment options on clinical trials. Clinical trial enrollment should be considered for all intimal sarcomas, and further exploration of copy number changes and genetic alterations is needed for this relatively chemotherapy-resistant disease. A global multicenter prospective registry/trial would best determine the response of this rare cancer to targeted therapies.
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![Sarcoma sample counts in American Association for Cancer Research Genomics Evidence Neoplasia Information Exchange (AACR GENIE). Color represents sarcoma subtypes as shown in the legend.](cancers-11-01283-g001){#cancers-11-01283-f001}

![Copy number alterations in intimal sarcoma. Genes are shown in columns for patients in rows. Red color represents copy number gain while green denotes loss. The numbers show the copy number alteration (CNA) values from AACR GENIE.](cancers-11-01283-g002){#cancers-11-01283-f002}

cancers-11-01283-t001_Table 1

###### 

Patient characteristics of the AACR GENIE intimal sarcoma patients.

  Patient      Cancer Type Detailed   Sample Type Detailed          Age at Seq Report   Sex      Primary Race   Ethnicity
  ------------ ---------------------- ----------------------------- ------------------- -------- -------------- --------------------------
  Patient 1    Intimal Sarcoma        Metastasis site unspecified   26                  Male     Asian          Non-Spanish/non-Hispanic
  Patient 2    Intimal Sarcoma        Primary tumor                 20                  Male     White          Non-Spanish/non-Hispanic
  Patient 3    Intimal Sarcoma        Metastasis site unspecified   42                  Male     White          Non-Spanish/non-Hispanic
  Patient 4    Intimal Sarcoma        Primary tumor                 47                  Female   White          Non-Spanish/non-Hispanic
  Patient 5    Intimal Sarcoma        Primary tumor                 46                  Female   Asian          Non-Spanish/non-Hispanic
  Patient 6    Intimal Sarcoma        Primary tumor                 18                  Female   White          Spanish/Hispanic
  Patient 7    Intimal Sarcoma        Primary tumor                 34                  Male     White          Non-Spanish/non-Hispanic
  Patient 8    Intimal Sarcoma        Primary tumor                 69                  Female   White          Non-Spanish/non-Hispanic
  Patient 9    Intimal Sarcoma        Metastasis site unspecified   76                  Female   White          Non-Spanish/non-Hispanic
  Patient 10   Intimal Sarcoma        Primary tumor                 56                  Female   White          Non-Spanish/non-Hispanic
  Patient 11   Intimal Sarcoma        Primary tumor                 46                  Male     White          Non-Spanish/non-Hispanic
  Patient 12   Intimal Sarcoma        Primary tumor                 71                  Female   White          Non-Spanish/non-Hispanic
  Patient 13   Intimal Sarcoma        Primary tumor                 49                  Female   Asian          Unknown

cancers-11-01283-t002_Table 2

###### 

Somatic mutations in intimal sarcoma samples. Potentially actionable genes are highlighted in green. (Potentially actionable genes are highlighted in green.)

  Sample       Gene       Variant Classification   Mutation
  ------------ ---------- ------------------------ --------------
  Patient 1    ASXL1      Missense                 D864E
  Patient 1    ASXL1      Missense                 G1299R
  Patient 1    GLI1       Missense                 R171Q
  Patient 1    IDH2       Missense                 I153V
  Patient 1    KDR        Splice Region            
  Patient 1    MDM2       Intron                   
  Patient 1    MYD88      Silent                   D247D
  Patient 1    NF1        Missense                 L121V
  Patient 1    RARA       Intron                   
  Patient 1    RET        Missense                 M1009T
  Patient 1    SETBP1     Missense                 P1526Q
  Patient 2    ARHGEF12   Missense                 E186K
  Patient 2    KDM5A      Missense                 S1408N
  Patient 2    TMEM127    Missense                 I188V
  Patient 2    TOPBP1     Missense                 L1499P
  Patient 3    ERBB4      Missense                 H893R
  Patient 5    BARD1      Missense                 A502N
  Patient 5    ERCC5      Missense                 S453C
  Patient 5    SOX2       Missense                 A263E
  Patient 5    TP53       Missense                 R273C
  Patient 5    U2AF1      Missense                 G212A
  Patient 7    ATR        Missense                 D1568E
  Patient 7    CDKN1A     Frame Shift Del          R140Qfs\*56
  Patient 7    FAT1       Missense                 P1333L
  Patient 7    PDGFRB     Missense                 D850V
  Patient 7    PTCH1      Missense                 L321I
  Patient 7    RECQL4     Missense                 E37K
  Patient 8    ALK        Missense                 E1460Q
  Patient 8    GATA1      Missense                 G165S
  Patient 8    GRIN2A     Missense                 R1309Q
  Patient 8    INPP4A     Missense                 P773S
  Patient 8    JAK3       Missense                 W716R
  Patient 8    NOTCH4     Missense                 A1439T
  Patient 8    PAK7       Frame Shift Del          P612Lfs\*3
  Patient 10   PDGFRB     Missense                 M772V
  Patient 11   EIF1AX     Missense                 G6R
  Patient 11   ERCC2      Missense                 T49A
  Patient 11   MDM4       Missense                 D173H
  Patient 11   NSD1       Nonsense                 Q2274\*
  Patient 11   SETD2      Frame Shift Del          V1070Lfs\*44
  Patient 12   EP300      Missense                 S2404A
  Patient 12   HGF        Frame Shift Ins          T4Gfs\*39
  Patient 13   ATM        Intron                   

cancers-11-01283-t003_Table 3

###### 

Gene fusions in intimal sarcoma. Comments are from the GENIE database.

  Sample       Fusion           DNA Support   RNA Support   Frame      Comments
  ------------ ---------------- ------------- ------------- ---------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient 7    PDE4DIP-NOTCH2   yes           unknown       in frame   Note: The PDE4DIP (NM_022359)-NOTCH2 (NM_024408) rearrangement event is a deletion which results in the fusion of PDE4DIP exon 1 and NOTCH2 exons 27--34. Its functional significance is undetermined.
  Patient 10   MRPS30-ARID2     yes           unknown       unknown    ARID2 (NM_152641) rearrangement: t(5;12) (p12;q12) (chr5:g.44601610::chr12:g.46245800) Note: The ARID2 rearrangement is a translocation which results in the truncation of ARID2 exons 15--21. One of the breakpoints is within ARID2 exon15.

[^1]: These authors contributed equally to this study.
